Rethink Medical SL

Rethink Medical SL, founded in 2014 at the Science and Technology Park of Las Palmas de Gran Canaria, Spain, is leading a paradigm shift in urological medical devices. Our flagship product, T-Control®, is the first urinary catheter with a fully integrated fluid control valve, designed to solve the long-standing clinical, economic, and human limitations of conventional catheters—unchanged for nearly a century.

The Problem We Solve
Traditional catheters are associated with high risks of infection (CAUTIs), poor patient quality of life, exposure of healthcare workers to biofluids, and substantial healthcare costs. They also generate significant plastic waste. T-Control® was conceived from real-world clinical experience and refined through a business-driven innovation model, co-led by a seasoned nurse and a healthcare business expert.

Our Solution: T-Control®
Thanks to its patented design, T-Control® prevents infections through a multifactorial mechanism, improves patient comfort and autonomy, and enhances healthcare efficiency. It enables intuitive urine flow control without requiring external bags and supports safe, one-person insertion—making it a safer, smarter alternative. It also allows optional use with collection bags, offering full adaptability.

Traction and Validation

• CE Mark obtained (TÜV SÜD, 2025)
• ISO 13485 (BSI) certified QMS
• Ongoing multicenter clinical trials in Spain and Portugal
• Proven cost-effectiveness model (Markov-based)
• Eight scientific publications and international conference presentations
• Over €3.9M in funding: including EIC Accelerator, CDTI, and Next Gen EU grants
• Manufacturing partnerships established
• Commercial discussions underway with global MedTech leaders
• Recognized by Forbes, APTE, EIT Health, and multiple EU innovation awards

Market & Commercial Strategy
The global urinary catheter market is projected to reach $4.1B by 2028. T-Control® is positioned as a premium, value-added product priced at €25–30 per unit. Our model includes exclusivity milestone payments (€20M targeted in 2027), 5% royalties, and potential production margins. Initial launches will target Europe and the U.S. through established MedTech distribution partners.

Upcoming Milestones & Investment Opportunity
We are seeking €1M in funding to finalize international regulatory registrations (FDA, UK), scale production, and expand clinical evidence. A €2M equity round is planned for H2 2026 to support market rollout. Current company valuation is €7.71M (pre-money 2024), with the founders retaining a 68% stake. An exit is anticipated in 2029 via acquisition or secondary buyout.

Impact
T-Control® not only reduces infections and total patient costs, but also significantly improves autonomy, safety, and dignity in patient care—while lowering environmental waste and antibiotic use. It has been enthusiastically validated by patients, clinicians, and health authorities.

Rethink Medical is ready to scale. With CE certification secured, proven innovation, and a solid go-to-market strategy, we invite strategic investors to join us in transforming urological care worldwide.